Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02025712Phase 2Unknown

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Role: lead

NCT01709370Phase 2Unknown

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

Role: lead

NCT00135018Phase 2Completed

Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer

Role: lead

NCT01088893Phase 2Unknown

Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy

Role: lead

NCT00509509Unknown

High Risk Breast Cancer Screening Program

Role: lead

All 5 trials loaded